Another Nrf2 activator oltipraza is reported to prevent, intervene and mitigate colon and liver cancer, hepatic fibrosis and nonalcoholic fatty liver disease (NAFLD) [138]. The gene discussed is NFE2L2; the disease is metabolic dysfunction-associated steatotic liver disease.